title: World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials.
abstract: The WHO/ILAR core set of endpoints for rheumatoid arthritis clinical trials signifies progress in a continuing worldwide effort. This core set includes the following measures: pain, patient global assessment, physical disability, swollen joints, tender joints, acute phase reactants, and physician global assessment; in studies of one or more years' duration, radiographs of joints should be performed.
authors.affiliation: Department of Internal Medicine/Rheumatology, University Hospital Maastricht, The Netherlands.
authors.forename: M
authors.initials: M
authors.lastname: Boers
authors.forename: P
authors.initials: P
authors.lastname: Tugwell
authors.forename: D T
authors.initials: DT
authors.lastname: Felson
authors.forename: P L
authors.initials: PL
authors.lastname: van Riel
authors.forename: J R
authors.initials: JR
authors.lastname: Kirwan
authors.forename: J P
authors.initials: JP
authors.lastname: Edmonds
authors.forename: J S
authors.initials: JS
authors.lastname: Smolen
authors.forename: N
authors.initials: N
authors.lastname: Khaltaev
authors.forename: K D
authors.initials: KD
authors.lastname: Muirden
mesh_terms: D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000150:complications* / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D006801:Humans; D012219:Rheumatology; D012720:Severity of Illness Index; D012955:Societies, Medical; D016896:Treatment Outcome; D014944:World Health Organization
chemical_list: D018501:Antirheumatic Agents